Bellerophon Therapeutics rises on enrollment completion for lung disease therapy trial

Bellerophon Therapeutics

18/01/2023 22:48

** Shares of drug developer Bellerophon Therapeutics Inc 
 BLPH.O  rise ~13% to 2.77 after the bell
    ** Co says it has completed its enrollment for its
late-stage study of its therapy INOpulse, for the treatment of a
type of lung disease
    ** Expects to report data from study in mid-2023 - BLPH
    ** INOpulse is a proprietary pulsatile nitric oxide delivery
system which is being studied for the treatment of fibrotic
interstitial lung disease 
    ** Stock lost ~71% last year
 (Reporting by Sriparna Roy)
 ((Sriparna.Roy@thomsonreuters.com;))